Is prostate cancer screening responsible for the negative results of prostate cancer treatment trials?

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Clinical guidelines continue to move away from routine prostate specific antigen screening (PSA), once a widespread medical practice. A curious difference exists between early prostate cancer and early breast cancer. While randomized trials of therapy in early breast cancer continue to show overall survival benefit, this is not the case in prostate cancer, where prostatectomy was no better than observation in a recent trial, and where early androgen deprivation is no better than late androgen deprivation. Here, I make the case that prostate cancer screening contributes so greatly to over diagnosis that even treatment trials yield null results due to contamination with non-life threatening disease.

Original languageEnglish (US)
Pages (from-to)71-73
Number of pages3
JournalMedical Hypotheses
Volume93
DOIs
StatePublished - Aug 1 2016

Fingerprint

Early Detection of Cancer
Prostatic Neoplasms
Breast Neoplasms
Androgens
Prostate-Specific Antigen
Prostatectomy
Observation
Guidelines
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Is prostate cancer screening responsible for the negative results of prostate cancer treatment trials? / Prasad, Vinay.

In: Medical Hypotheses, Vol. 93, 01.08.2016, p. 71-73.

Research output: Contribution to journalArticle

@article{25535290c1184036b4be121339e559a9,
title = "Is prostate cancer screening responsible for the negative results of prostate cancer treatment trials?",
abstract = "Clinical guidelines continue to move away from routine prostate specific antigen screening (PSA), once a widespread medical practice. A curious difference exists between early prostate cancer and early breast cancer. While randomized trials of therapy in early breast cancer continue to show overall survival benefit, this is not the case in prostate cancer, where prostatectomy was no better than observation in a recent trial, and where early androgen deprivation is no better than late androgen deprivation. Here, I make the case that prostate cancer screening contributes so greatly to over diagnosis that even treatment trials yield null results due to contamination with non-life threatening disease.",
author = "Vinay Prasad",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.mehy.2016.05.019",
language = "English (US)",
volume = "93",
pages = "71--73",
journal = "Medical Hypotheses",
issn = "0306-9877",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Is prostate cancer screening responsible for the negative results of prostate cancer treatment trials?

AU - Prasad, Vinay

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Clinical guidelines continue to move away from routine prostate specific antigen screening (PSA), once a widespread medical practice. A curious difference exists between early prostate cancer and early breast cancer. While randomized trials of therapy in early breast cancer continue to show overall survival benefit, this is not the case in prostate cancer, where prostatectomy was no better than observation in a recent trial, and where early androgen deprivation is no better than late androgen deprivation. Here, I make the case that prostate cancer screening contributes so greatly to over diagnosis that even treatment trials yield null results due to contamination with non-life threatening disease.

AB - Clinical guidelines continue to move away from routine prostate specific antigen screening (PSA), once a widespread medical practice. A curious difference exists between early prostate cancer and early breast cancer. While randomized trials of therapy in early breast cancer continue to show overall survival benefit, this is not the case in prostate cancer, where prostatectomy was no better than observation in a recent trial, and where early androgen deprivation is no better than late androgen deprivation. Here, I make the case that prostate cancer screening contributes so greatly to over diagnosis that even treatment trials yield null results due to contamination with non-life threatening disease.

UR - http://www.scopus.com/inward/record.url?scp=84969961755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969961755&partnerID=8YFLogxK

U2 - 10.1016/j.mehy.2016.05.019

DO - 10.1016/j.mehy.2016.05.019

M3 - Article

VL - 93

SP - 71

EP - 73

JO - Medical Hypotheses

JF - Medical Hypotheses

SN - 0306-9877

ER -